Department of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.
Advanced Imaging Research Center, Oregon Health & Science University, Portland, Oregon, USA.
Neuro Oncol. 2021 Jul 1;23(7):1056-1071. doi: 10.1093/neuonc/noab020.
Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, and response assessment. Institutional imaging variation and inconsistent clinical trial reporting diminishes the reliability and reproducibility of clinical response assessment. In this context, we aimed to: (1) critically review the use of advanced positron emission tomography (PET) and magnetic resonance imaging (MRI) in the setting of PCNSL; (2) provide results from an international survey of clinical sites describing the current practices for routine and advanced imaging, and (3) provide biologically based recommendations from the International PCNSL Collaborative Group (IPCG) on adaptation of standardized imaging practices. The IPCG provides PET and MRI consensus recommendations built upon previous recommendations for standardized brain tumor imaging protocols (BTIP) in primary and metastatic disease. A biologically integrated approach is provided to addresses the unique challenges associated with the imaging assessment of PCNSL. Detailed imaging parameters facilitate the adoption of these recommendations by researchers and clinicians. To enhance clinical feasibility, we have developed both "ideal" and "minimum standard" protocols at 3T and 1.5T MR systems that will facilitate widespread adoption.
对原发性中枢神经系统淋巴瘤 (PCNSL) 的先进分子和病理生理学特征的深入研究揭示了有前途的靶向治疗方法。医学影像学在 PCNSL 的诊断、分期和反应评估中起着至关重要的作用。机构间成像的差异和临床试验报告的不一致性降低了临床反应评估的可靠性和可重复性。在这种情况下,我们旨在:(1) 批判性地审查高级正电子发射断层扫描 (PET) 和磁共振成像 (MRI) 在 PCNSL 中的应用;(2) 提供来自国际临床站点的调查结果,描述常规和高级成像的当前实践,以及 (3) 提供国际 PCNSL 协作组 (IPCG) 的基于生物学的建议,以适应标准化的成像实践。IPCG 提供了 PET 和 MRI 共识建议,这些建议是基于以前对原发性和转移性疾病标准化脑肿瘤成像方案 (BTIP) 的建议制定的。提供了一种生物学综合方法来解决与 PCNSL 成像评估相关的独特挑战。详细的成像参数有助于研究人员和临床医生采用这些建议。为了增强临床可行性,我们在 3T 和 1.5T MR 系统上开发了“理想”和“最低标准”协议,这将促进广泛采用。